Practical guidelines for the diagnosis and treatment of transthyretin amyloid cardiomyopathy (ATTR-CM or transthyretin cardiac amyloidosis)
- Authors: Tereshchenko S.N.1,2, Zhirov I.V.1,2, Moiseeva O.M.3,4, Adasheva T.V.5, Ansheles A.A.1, Barbarash O.L.6,7, Galyavich A.S.8, Gudkova A.I.3,4, Zateyshchikov D.A.9,10, Kostareva A.A.3, Nasonova S.N.1, Nedogoda S.V.11, Pecherina T.B.6, Ryzhkova D.V.3, Sergienko V.B.1
-
Affiliations:
- Chazov National Medical Research Center of Cardiology
- Russian Medical Academy of Continuous Professional Education
- Almazov National Medical Research Centre
- Pavlov First Saint Petersburg State Medical University
- Yevdokimov Moscow State University of Medicine and Dentistry
- Research Institute of Complex Problems of Cardiovascular Diseases
- Kemerovo State Medical University
- Kazan State Medical University
- City Clinical Hospital №51
- Central State Medical Academy of the President of the Russian Federation
- Volgograd State Medical University
- Issue: Vol 94, No 4 (2022)
- Pages: 584-595
- Section: Reviews
- URL: https://journals.rcsi.science/0040-3660/article/view/108262
- DOI: https://doi.org/10.26442/00403660.2022.04.201465
- ID: 108262
Cite item
Full Text
Abstract
This paper summarizes the data from updated international protocols and guidelines for diagnosis of transthyretin amyloid cardiomyopathy (ATTR-CM). The invasive and non-invasive diagnosis techniques and their combinations are briefly reviewed; the evidentiary foundations for each diagnostic option and tool are analyzed. The paper describes a customized algorithm for sequential diagnosis and differential diagnosis of patients with suspected ATTR-CM with allowance for the combination of clinical signs and diagnostic findings. Along with the awareness of primary care providers about the red flags of the disease and visualization criteria, as well as providing information to the patients about the possibility of performing therapy of ATTR amyloidosis and the risks of delayed diagnosis, the proposed algorithm enables timely patient routing and prescribing specific treatment.
Full Text
##article.viewOnOriginalSite##About the authors
Sergey N. Tereshchenko
Chazov National Medical Research Center of Cardiology; Russian Medical Academy of Continuous Professional Education
Email: izhirov@mail.ru
ORCID iD: 0000-0001-9234-6129
д-р мед. наук, проф., рук. отд. заболеваний миокарда и сердечной недостаточности, зав. каф. кардиологии
Russian Federation, Moscow; MoscowIgor V. Zhirov
Chazov National Medical Research Center of Cardiology; Russian Medical Academy of Continuous Professional Education
Author for correspondence.
Email: izhirov@mail.ru
ORCID iD: 0000-0002-4066-2661
д-р мед. наук, вед. науч. сотр., проф. каф. кардиологии
Russian Federation, Moscow; MoscowOlga M. Moiseeva
Almazov National Medical Research Centre; Pavlov First Saint Petersburg State Medical University
Email: izhirov@mail.ru
ORCID iD: 0000-0002-7817-3847
д-р мед. наук, дир. Института сердца и сосудов, рук. отд. некоронарогенных заболеваний сердца, проф. каф. факультетской терапии
Russian Federation, Saint Petersburg; Saint PetersburgTatiana V. Adasheva
Yevdokimov Moscow State University of Medicine and Dentistry
Email: izhirov@mail.ru
ORCID iD: 0000-0002-3763-8994
д-р мед. наук, проф. каф. поликлинической терапии, чл. президиума РНМОТ
Russian Federation, MoscowAlexey A. Ansheles
Chazov National Medical Research Center of Cardiology
Email: izhirov@mail.ru
ORCID iD: 0000-0002-2675-3276
д-р мед. наук, вед. науч. сотр. отд. радионуклидной диагностики и позитронно-эмиссионной томографии
Russian Federation, MoscowOlga L. Barbarash
Research Institute of Complex Problems of Cardiovascular Diseases; Kemerovo State Medical University
Email: izhirov@mail.ru
ORCID iD: 0000-0002-4642-3610
чл.-кор. РАН, д-р мед. наук, проф., дир., зав. каф. кардиологии
Russian Federation, Kemerovo; KemerovoAlbert S. Galyavich
Kazan State Medical University
Email: izhirov@mail.ru
ORCID iD: 0000-0002-4510-6197
д-р мед. наук, проф., зав. каф. кардиологии фак-та повышения квалификации и профессиональной переподготовки специалистов
Russian Federation, KazanAlexandra Ia. Gudkova
Almazov National Medical Research Centre; Pavlov First Saint Petersburg State Medical University
Email: izhirov@mail.ru
ORCID iD: 0000-0003-0156-8821
д-р мед. наук, вед. науч. сотр. Института молекулярной биологии и генетики, зав. лаб. кардиомиопатий НИИ сердечно- сосудистых заболеваний Научно-клинического исследовательского центра, проф. каф. факультетской терапии
Russian Federation, Saint Petersburg; Saint PetersburgDmitry A. Zateyshchikov
City Clinical Hospital №51; Central State Medical Academy of the President of the Russian Federation
Email: izhirov@mail.ru
ORCID iD: 0000-0001-7065-2045
д-р мед. наук, проф., зав. первичным сосудистым отд-нием, зав. каф. терапии, кардиологии и функциональной диагностики с курсом нефрологии
Russian Federation, Moscow; MoscowAnna A. Kostareva
Almazov National Medical Research Centre
Email: izhirov@mail.ru
ORCID iD: 0000-0002-9349-6257
д-р мед. наук, дир. Института молекулярной биологии и генетики
Russian Federation, Saint PetersburgSvetlana N. Nasonova
Chazov National Medical Research Center of Cardiology
Email: izhirov@mail.ru
ORCID iD: 0000-0002-0920-7417
канд. мед. наук, ст. науч. сотр. отд. заболеваний миокарда и сердечной недостаточности НИИ клинической кардиологии им. А.Л. Мясникова
Russian Federation, MoscowSergey V. Nedogoda
Volgograd State Medical University
Email: izhirov@mail.ru
ORCID iD: 0000-0001-5981-1754
д-р мед. наук, проф., зав. каф. внутренних болезней Института непрерывного медицинского и фармацевтического образования
Russian Federation, VolgogradTamara B. Pecherina
Research Institute of Complex Problems of Cardiovascular Diseases
Email: izhirov@mail.ru
ORCID iD: 0000-0002-4771-484X
канд. мед. наук, доц., ст. науч. сотр. лаб. патологии кровообращения отд. клинической кардиологии
Russian Federation, KemerovoDaria V. Ryzhkova
Almazov National Medical Research Centre
Email: d_ryjkova@mail.ru
ORCID iD: 0000-0002-7086-9153
д-р мед. наук, проф., врач-радиолог высшей категории, гл. науч. сотр. научно-исследовательского отд. ядерной медицины и тераностики Института онкологии и гематологии, рук. научно-клинического объединения ядерной медицины, зав. каф. ядерной медицины и радиационных технологий Института медицинского образования
Russian Federation, Saint PetersburgVladimir B. Sergienko
Chazov National Medical Research Center of Cardiology
Email: izhirov@mail.ru
ORCID iD: 0000-0002-0487-6902
д-р мед. наук, проф., рук. отд. радионуклидной диагностики и позитронно-эмиссионной томографии
Russian Federation, MoscowReferences
- Ruberg FL, Grogan M, Hanna M, et al. Transthyretin Amyloid Cardiomyopathy: JACC State-of-the-Art Review. J Am Coll Cardiol. 2019;73(22):2872-91. doi: 10.1016/j.jacc.2019.04.003
- Garcia-Pavia P, Rapezzi C, Adler Y, et al. Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2021;42(16):1554-68. doi: 10.1093/eurheartj/ehab072
- Witteles RM, Bokhari S, Damy T, et al. Screening for Transthyretin Amyloid Cardiomyopathy in Everyday Practice. JACC Hear Fail. 2019;7(8):709-16. doi: 10.1016/j.jchf.2019.04.010
- Wechalekar AD, Gillmore JD, Hawkins PN. Systemic amyloidosis. Lancet. 2016;387(10038):2641-54. doi: 10.1016/S0140-6736(15)01274-X
- Benson MD, Buxbaum JN, Eisenberg DS, et al. Amyloid nomenclature 2018: recommendations by the International Society of Amyloidosis (ISA) nomenclature committee. Amyloid. 2018;25(4):215-9. doi: 10.1080/13506129.2018.1549825
- Narotsky DL, Castano A, Weinsaft JW, et al. Wild-type Transthyretin Cardiac Amyloidosis: Novel Insights from Advanced Imaging. Can J Cardiol. 2016;32(9):1166.e1-10. doi: 10.1016/j.cjca.2016.05.008
- González-López E, López-Sainz Á, Garcia-Pavia P. Diagnosis and Treatment of Transthyretin Cardiac Amyloidosis. Progress and Hope. Rev Española Cardiol. 2017;70(11):991-1004. doi: 10.1016/j.rec.2017.05.036
- Benson MD, Buxbaum JN, Eisenberg DS, et al. Amyloid nomenclature 2020: update and recommendations by the International Society of Amyloidosis (ISA) nomenclature committee. Amyloid. 2020;27(4):217-22. doi: 10.1080/13506129.2020.1835263
- Kitaoka H, Izumi C, Izumiya Y, et al. JCS 2020 guideline on diagnosis and treatment of cardiac amyloidosis. Circ J. 2020;84(9):1610-71. doi: 10.1253/circj.CJ-20-0110.
- Резник Е.В., Нгуен Т.Л., Степанова Е.А., и др. Амилоидоз сердца: взгляд терапевта и кардиолога. Архивъ внутренней медицины. 2020;10(6):430-57 [Reznik EV, Nguyen TL, Stepanova EA, et al. Cardiac Amyloidosis: Internist and Cardiologist Insight. Russ Arch Intern Med. 2020;10(6):430-57 (in Russian)]. doi: 10.20514/2226-6704-2020-10-6-430-457
- Rapezzi C, Merlini G, Quarta CC, et al. Systemic cardiac amyloidoses: Disease profiles and clinical courses of the 3 main types. Circulation. 2009;120(13):1203-12. doi: 10.1161/CIRCULATIONAHA.108.843334
- Gillmore JD, Maurer MS, Falk RH, et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation. 2016;133(24):2404-12. doi: 10.1161/CIRCULATIONAHA.116.021612
- Conceição I, Damy T, Romero M, et al. Early diagnosis of ATTR amyloidosis through targeted follow-up of identified carriers of TTR gene mutations. Amyloid. 2019;26(1):3-9. doi: 10.1080/13506129.2018.1556156
- Akinboboye O, Shah K, Warner AL, et al. DISCOVERY: prevalence of transthyretin (TTR) mutations in a US-centric patient population suspected of having cardiac amyloidosis. Amyloid. 2020;27(4):223-30. doi: 10.1080/13506129.2020.1764928
- Yamashita T, Ueda M, Misumi Y, et al. Genetic and clinical characteristics of hereditary transthyretin amyloidosis in endemic and non-endemic areas: experience from a single-referral center in Japan. J Neurol. 2018;265(1):134-40. doi: 10.1007/s00415-017-8640-7
- Golbus JR, Wells JM, Dickinson MG, Hummel SL. Importance of Genetic Testing in the Diagnosis of Transthyretin Cardiac Amyloidosis. Am J Med. 2018;131(7):e303-4. doi: 10.1016/j.amjmed.2018.02.005
- Rowczenio D, Quarta CC, Fontana M, et al. Analysis of the TTR gene in the investigation of amyloidosis: A 25-year single UK center experience. Hum Mutat. 2019;40(1):90-6. doi: 10.1002/humu.23669
- Cheng RK, Vasbinder A, Levy WC, et al. Lack of Association Between Neurohormonal Blockade and Survival in Transthyretin Cardiac Amyloidosis. J Am Heart Assoc. 2021;10(24):e022859. doi: 10.1161/JAHA.121.022859
- Насонова С.Н., Жиров И.В., Магомедов М.М., и др. Опыт применения тафамидиса у пациентки с транстиретиновым амилоидозом. Кардиология. 2020;60(3):155-60 [Nasonova SN, Zhirov IV, Magomedov MM, et al. Experience with tafamidis in a patient with transthyretin amyloidosis. Kardiologiya. 2020;60(3):155-60 (in Russian)]. doi: 10.18087/cardio.2020.3.n824
- Dorbala S, Ando Y, Bokhari S, et al. ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 1 of 2–evidence base and standardized methods of imaging. J Nucl Cardiol. 2019;26(6):2065-123. doi: 10.1007/s12350-019-01760-6
- Kurian SM, Novais M, Whisenant T, et al. Peripheral blood cell gene expression diagnostic for identifying symptomatic transthyretin amyloidosis patients: Male and female specific signatures. Theranostics. 2016;6(11):1792-809. doi: 10.7150/thno.14584
- Obici L, Kuks JB, Buades J, et al. Recommendations for presymptomatic genetic testing and management of individuals at risk for hereditary transthyretin amyloidosis. Curr Opin Neurol. 2016;29:S27-35. doi: 10.1097/WCO.0000000000000290
- Lahuerta Pueyo C, Aibar Arregui MÁ, Gracia Gutierrez A, et al. Estimating the prevalence of allelic variants in the transthyretin gene by analysing large-scale sequencing data. Eur J Hum Genet. 2019;27(5):783-91. doi: 10.1038/s41431-019-0337-1
- Maurer MS. Non-invasive Identification of ATTRwt Cardiac Amyloid (aka Senile Cardiac Amyloid): The Re-emergence of Nuclear Cardiology. Am J Med. 2015;155(1):3-12. doi: 10.1016/j.amjmed.2015.05.039
- Kazi DS, Bellows BK, Baron SJ, et al. Cost-effectiveness of tafamidis therapy for transthyretin amyloid cardiomyopathy. Circulation. 2020;141(15):1214-24. doi: 10.1161/CIRCULATIONAHA.119.045093
- Bistola V, Parissis J, Foukarakis E, et al. Practical recommendations for the diagnosis and management of transthyretin cardiac amyloidosis. Heart Fail Rev. 2021;26(4):861-79. doi: 10.1007/s10741-020-10062-w
- Yilmaz A, Bauersachs J, Bengel F, et al. Diagnosis and treatment of cardiac amyloidosis: position statement of the German Cardiac Society (DGK). Clin Res Cardiol. 2021;110(4):479-506. doi: 10.1007/s00392-020-01799-3
- Maurer MS, Schwartz JH, Gundapaneni B, et al. Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy. N Engl J Med. 2018;379(11):1007-16. doi: 10.1056/NEJMoa1805689
- Dorbala S, Ando Y, Bokhari S, et al. ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 2 of 2 – Diagnostic criteria and appropriate utilization. J Nucl Cardiol. 2020;27(2):659-73. doi: 10.1007/s12350-019-01761-5
- Ando Y, Coelho T, Berk JL, et al. Guideline of transthyretin-related hereditary amyloidosis for clinicians. Orphanet J Rare Dis. 2013;8(1):1-18. doi: 10.1186/1750-1172-8-31
- Bonderman D, Pölzl G, Ablasser K, et al. Diagnosis and treatment of cardiac amyloidosis: an interdisciplinary consensus statement. Wien Klin Wochenschr. 2020;132(23-24):742-61. doi: 10.1007/s00508-020-01781-z
- Caobelli F, Braun M, Haaf P, et al. Quantitative 99mTc-DPD SPECT/CT in patients with suspected ATTR cardiac amyloidosis: Feasibility and correlation with visual scores. J Nucl Cardiol. 2020;27(5):1456-63. doi: 10.1007/s12350-019-01893-8
- Conceição I, Coelho T, Rapezzi C, et al. Assessment of patients with hereditary transthyretin amyloidosis – understanding the impact of management and disease progression. Amyloid. 2019;26(3):103-11. doi: 10.1080/13506129.2019.1627312
- Maurer MS, Bokhari S, Damy T, et al. Expert Consensus Recommendations for the Suspicion and Diagnosis of Transthyretin Cardiac Amyloidosis. Circ Hear Fail. 2019;12(9):1-11. doi: 10.1161/CIRCHEARTFAILURE.119.006075
- Musumeci MB, Cappelli F, Russo D, et al. Low Sensitivity of Bone Scintigraphy in Detecting Phe64Leu Mutation-Related Transthyretin Cardiac Amyloidosis. JACC Cardiovasc Imaging. 2020;13(6):1314-21. doi: 10.1016/j.jcmg.2019.10.015.
- Park GY, Jamerlan A, Shim KH, An SSA. Diagnostic and treatment approaches involving transthyretin in amyloidogenic diseases. Int J Mol Sci. 2019;20(12). doi: 10.3390/ijms20122982
- Maurer MS, Elliott P, Comenzo R, et al. Addressing Common Questions Encountered in the Diagnosis and Management of Cardiac Amyloidosis. Circulation. 2017;135(14):1357-77. doi: 10.1161/CIRCULATIONAHA.116.024438
- Rubina J, Steidleyb DE, Carlssonc M, et al. Myocardial Contraction Fraction by M-Mode Echocardiography is Superior to Ejection Fraction in Predicting Mortality in Transthyretin Amyloidosis. J Card Fail. 2018;24(8):504-11. doi: 10.1016/j.cardfail.2018.07.001
- Borlaug BA, Paulus WJ. Heart failure with preserved ejection fraction: Pathophysiology, diagnosis, and treatment. Eur Heart J. 2011;32(6):670-9. doi: 10.1093/eurheartj/ehq426
- Kittleson MM, Maurer MS, Ambardekar AV, et al. Cardiac Amyloidosis: Evolving Diagnosis and Management: A Scientific Statement from the American Heart Association. Circulation. 2020;142(1):E7-22. doi: 10.1161/CIR.0000000000000792
- Tanskanen M, Peuralinna T, Polvikoski T, et al. Senile systemic amyloidosis affects 25% of the very aged and associates with genetic variation in alpha2-macroglobulin and tau: A population-based autopsy study. Ann Med. 2008;40(3):232-9. doi: 10.1080/07853890701842988
- Lysenko (Kozlovskaya) LV, Rameev VV, Moiseev S, et al. Clinical guidelines for diagnosis and treatment of systemic amyloidosis. Clin Pharmacol Ther. 2020;29(1):13-24. doi: 10.32756/0869-5490-2020-1-13-24
- Rosenblum H, Masri A, Narotsky DL, et al. Unveiling outcomes in coexisting severe aortic stenosis and transthyretin cardiac amyloidosis. Eur J Heart Fail. 2021;23(2):250-8. doi: 10.1002/ejhf.1974
- Hutt DF, Quigley AM, Page J, et al. Utility and limitations of 3,3-diphosphono-1, 2-propanodicarboxylic acid scintigraphy in systemic amyloidosis. Eur Heart J Cardiovasc Imaging. 2014;15(11):1289-98. doi: 10.1093/ehjci/jeu107
- Poterucha TJ, Elias P, Bokhari S, et al. Diagnosing Transthyretin Cardiac Amyloidosis by Technetium Tc 99m Pyrophosphate: A Test in Evolution. JACC Cardiovasc Imaging. 2021;14(6):1221-31. doi: 10.1016/j.jcmg.2020.08.027
- Gertz M, Adams D, Ando Y, et al. Avoiding misdiagnosis: Expert consensus recommendations for the suspicion and diagnosis of transthyretin amyloidosis for the general practitioner. BMC Fam Pract. 2020;21(1):1-12. doi: 10.1186/s12875-020-01252-4
- Sprangers B, Claes K, Evenepoel P, et al. Comparison of 2 Serum-Free Light-Chain Assays in CKD Patients. Kidney Int Rep. 2020;5(5):627-31. doi: 10.1016/j.ekir.2020.01.019
- De Lillo A, De Angelis F, Di Girolamo M, et al. Phenome-wide association study of TTR and RBP4 genes in 361,194 individuals reveals novel insights in the genetics of hereditary and wildtype transthyretin amyloidoses. Hum Genet. 2019;138(11-12):1331-40. doi: 10.1007/s00439-019-02078-6
- Lane T, Fontana M, Martinez-Naharro A, et al. Natural History, Quality of Life, and Outcome in Cardiac Transthyretin Amyloidosis. Circulation. 2019;140(1):16-26. doi: 10.1161/CIRCULATIONAHA.118.038169
- López-Sainz Á, Hernandez-Hernandez A, Gonzalez-Lopez E, et al. Clinical profile and outcome of cardiac amyloidosis in a Spanish referral center. Rev Española Cardiol. 2021;74(2):149-58. doi: 10.1016/j.rec.2019.12.020
- Адян ТА., Поляков АВ. Наследственный транстиретиновый амилоидоз. Нервно-мышечные болезни. 2019;9(4):12-25 [Adyan TA, Polyakov AV. Hereditary transthyretin amyloidosis. Neuromuscular Diseases. 2019;9(4):12-25 (in Russian)]. doi: 10.17650/2222-8721-2019-9-4-12-25
- Siddiqi OK, Ruberg FL. Cardiac Amyloidosis: An Update on Pathophysiology, Diagnosis, and Treatment HHS Public Access Introduction and Classification. Trends Cardiovasc Med. 2018;28(1):10-21. doi: 10.1016/j.tcm.2017.07.004
- Adams D, Koike H, Slama M, Coelho T. Hereditary transthyretin amyloidosis: a model of medical progress for a fatal disease. Nat Rev Neurol. 2019;15(7):387-404. doi: 10.1038/s41582-019-0210-4
- Rapezzi C, Quarta CC, Riva L, et al. Transthyretin-related amyloidoses and the heart: A clinical overview. Nat Rev Cardiol. 2010;7(7):398-408. doi: 10.1038/nrcardio.2010.67
- Goyal A, Lahan S, Dalia T, et al. Clinical comparison of V122I genotypic variant of transthyretin amyloid cardiomyopathy with wild-type and other hereditary variants: a systematic review. Heart Fail Rev. 2021. doi: 10.1007/s10741-021-10098-6
- Garcia-Pavia P, Bengel F, Brito D, et al. Expert consensus on the monitoring of transthyretin amyloid cardiomyopathy. Eur J Heart Fail. 2021;23(6):895-905. doi: 10.1002/ejhf.2198
- Gertz MA, Comenzo R, Falk RH, et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis. Am J Hematol. 2005;79(4):319-28. doi: 10.1002/ajh.20381
- Yamamoto H, Yokochi T. Transthyretin cardiac amyloidosis: an update on diagnosis and treatment. ESC Hear Fail. 2019;6(6):1128-39. doi: 10.1002/ehf2.12518
- Damy T, Garcia-Pavia P, Hanna M, et al. Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and long-term extension study. Eur J Heart Fail. 2021;23(2):277-85. doi: 10.1002/ejhf.2027
- Cho Y, Baranczak A, Helmke S, et al. Personalized medicine approach for optimizing the dose of tafamidis to potentially ameliorate wild-type transthyretin amyloidosis (cardiomyopathy). Amyloid. 2015;22(3):175-80. doi: 10.3109/13506129.2015.1063485
- Adams D, Algalarrondo V, Polydefkis M, et al. Expert opinion on monitoring symptomatic hereditary transthyretin-mediated amyloidosis and assessment of disease progression. Orphanet J Rare Dis. 2021;16(1):411. doi: 10.1186/s13023-021-01960-9
- Chacko L, Martone R, Bandera F, et al. Echocardiographic phenotype and prognosis in transthyretin cardiac amyloidosis. Eur Heart J. 2020;41(14):1439-47a. doi: 10.1093/eurheartj/ehz905
- Nitsche C, Aschauer S, Kammerlander AA, et al. Light-chain and transthyretin cardiac amyloidosis in severe aortic stenosis: prevalence, screening possibilities, and outcome. Eur J Heart Fail. 2020;22(10):1852-62. doi: 10.1002/ejhf.1756
Supplementary files
![](/img/style/loading.gif)